MMRC announces Phase 1B Study of Elotuzumab (HuLuc63) Monoclonal Antibody in combination with REVLIMID and dexamethasone
The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a three-drug combination study of elotuzumab (also known as HuLuc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with REVLIMID(R) (lenalidomide), and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse.
Emory University's Winship Cancer Institute, Washington University, and St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York will evaluate the maximum tolerated dose of elotuzumab in combination with label dosing of lenalidomide and dexamethasone. The multi-center, open-label, dose-escalation Phase Ib study will enroll up to 26 patients.
"This three drug combination study is a pivotal study for patients with relapsed multiple myeloma as they may benefit from the synergistic effects of a new monoclonal antibody with two currently available drugs", said Principal Investigator, Sagar Lonial, MD, Associate Professor of Medicine, at Emory University's Winship Cancer Institute. "We look forward to testing this promising new combination."
About Elotuzumab
Elotuzumab (or HuLuc63) is a humanized monoclonal antibody under development by PDL BioPharma that binds to human CS1, a cell-surface glycoprotein that is highly and universally expressed on multiple myeloma cells but minimally expressed on normal cells. The antibody is currently being evaluated in Phase I clinical studies as a monotherapy and combination therapy for the treatment of relapsed multiple myeloma.
Emory University's Winship Cancer Institute, Washington University, and St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York will evaluate the maximum tolerated dose of elotuzumab in combination with label dosing of lenalidomide and dexamethasone. The multi-center, open-label, dose-escalation Phase Ib study will enroll up to 26 patients.
"This three drug combination study is a pivotal study for patients with relapsed multiple myeloma as they may benefit from the synergistic effects of a new monoclonal antibody with two currently available drugs", said Principal Investigator, Sagar Lonial, MD, Associate Professor of Medicine, at Emory University's Winship Cancer Institute. "We look forward to testing this promising new combination."
About Elotuzumab
Elotuzumab (or HuLuc63) is a humanized monoclonal antibody under development by PDL BioPharma that binds to human CS1, a cell-surface glycoprotein that is highly and universally expressed on multiple myeloma cells but minimally expressed on normal cells. The antibody is currently being evaluated in Phase I clinical studies as a monotherapy and combination therapy for the treatment of relapsed multiple myeloma.
posted by gwg at 7:50 PM
0 Comments:
Post a Comment
<< Home